The new research has been published in the AACC’s January Men’s Health Issue of the Clinical Chemistry journal. The American Association for Clinical Chemistry (AACC), is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare.
In the first study, a team of researchers led by Dina N. Greene, PhD, of the University of Washington in Seattle has found evidence of better outcomes related to blood clots in transgender women taking estrogen compared to premenopausal cisgender women taking oral contraceptives. Though the outcome showed a slightly higher rate of blood clots in transgender women taking estrogen (2.3 per 1,000 person-years) compared to the incidence rate of blood clots in the general population (1.0-1.8 per 1,000 person-years), it is less than the estimated rate in premenopausal women taking oral contraceptives (3.5 per 1,000 person-years). The results of the study show that transgender women who take estrogen are at a much lower risk for blood clots compared to cisgender women taking birth control pills.